Welcome & Introduction

Mediastinal & Systemic Staging for suspected stage III NSCLC

Role of Biomarkers in the management of advanced NSCLC

Experience sharing of IO in ES-SCLC

Panel Discussion- Optimal management of 1L ES SCLC Case Based Discussion

Experience sharing of IO in stage III NSCLC

Management of NSCLC stage III Evidence and Experience so far

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

Panel Discussion - Case Based Discussion Stage III NSCLC

Closing Remarks